Livagen (20mg)

What is the Livagen peptide?

Livagen is a short peptide bioregulator, similar in structure to Epitalon. Its effects appear to be exhibited directly on the lymphocytes of the immune system, liver, and GIT. Its direct functions may be widespread —as reported in research studies on DNA and gene expression patterns. The potential of the Livagen peptide to activate genes enclosed in the GIT and immune system may be due to its supposed anti-aging properties.

Specifications

Sequence Formula: Lys-Glu-Asp-Ala

Molecular Formula: C18H31N5O9

Molecular Weight: 461.5g/mol

PubChem: CID 87919683

Synonyms: SCHEMBL5967826

Reconstitution: Required

Research

Livagen Peptides: Studies in Chromatin and the Immune System
In eukaryotes, like humans, the nucleus houses the DNA. Chromatin is a group of DNA and proteins which condense to form chromosomes. This DNA organization pattern helps encapsulate genetic materials for cell division and replication, as well as genetic materials so they can fit into cells and control the expression of genes at gross levels. In studies on older adults, Livagen research suggests that the peptide may activate several genes in the lymphocytes by unpacking chromatin. Subsequently, silent genes are activated in older adults and indirectly activate the ribosomal genes in the control of protein production and increased cell activity. According to this research, Livagen appears to have four potential and distinct effects on lymphocytes, viz;
● altering gene expression
● aiding in decondensation
● activating ribosomal genes, which in turn activate synthetic processes.
● aiding in chromatin unpacking
Scientists believe that long-term administration of Livagen may possibly alter the lymphocytes to be expressed similarly to those in young persons. Lymphocytes are vital cells in the human immune system, containing both T and B cells. B cells act to produce antibodies against foreign bodies. T cells produce cytokines and destroy cancerous cells or infected cells. The proposed ability of Livagen to renew these cells may result in healthier cells in old age, aiding the body in deflecting cancer and diverse infections.

Livagen and Aging
The effects of aging result from changes in DNA organization, including the type of genes expressed and accessed. Research by Professor Teimuraz Lezhava reportes that the degree of chromosomal aberrations increases with age. The condensation of chromatin and the decreased repair processes are examples of a chromosomal oddity. According to his research, Livagen and a handful of other bioregulating peptides, may improve the decondensation of DNA leading to an extended lifespan. These pause dysfunctions may stem with age and are associated with immune dysregulation and reduced protein synthesis.

Livagen and the Heart
Lymphocytes are necessary ancillaries in the heart, hinting that the heart could be Livagen-sensitive. Research in patients with hypertrophic cardiomyopathy (HCM) sugguests that the dysregulation of the chromatin structure in lymphocytes is pathogenic in HCM and atherosclerosis and may improve long-term outcomes. Clinical studies further suggest that releasing genes by decondensed chromatin in lymphocytes could reduce the long-term consequences of heart diseases. Researchers posit that Livagen peptide has the potential to precipitate such a reduction, though research is ongoing. Alteration of lymphocyte gene expression shows a decrease in inflammation and scars in patients with HCM. Livagen may prevent the development of HCM in patients who are genetically predisposed to it. Following cardiac arrest or injuries, it may introduce an advanced approach to reducing the mortality and morbidity related to heart disease.

Livagen and the Gastrointestinal System (GIT)
Early research posits that activated delta cells may protect the mucosal wall of the gastrointestinal system (GIT). Following this trend, the Livagen peptide appears to enhance vagus nerve signaling to the GIT and changes the degree of prostaglandins and nitric oxide in the mucosa. In addition to this, gastroprotection may also be generated, creating a potential pathway for Livagen use in treating infectious diarrhea, inflammatory bowel disease, and overall reduction in symptoms of GIT disruption. Livagen’s proposed ability to enhance receptor activation by increasing enkephalin levels in the blood supports its potential in treating various disorders of the GIT.

Livagen and Pain
Enkephalin is a natural peptide that has a reported dynamic anti-pain killer effect. It appears to bind to delta and mu-opioid receptors. Thus, activated Mu receptors bind to morphine to decrease pain, consciousness, and blood pressure. Activated Delta receptors cause a reduction in the perception of pain and may explain respiratory depressions associated with opiates. Clinical studies suggest that Livagen functions to inhibit the actions of enkephalin inhibiting enzymes in the blood, resulting in enhanced levels of natural pain killers. This process supports the hypothesis that Livagen may become an effective pain treatment. Research is still ongoing to actuate its potency, the side effects of high levels of enkephalin, and if there is an addictive potential associated with it, as seen in other opioids.

Conclusion

Livagen is a promising peptide regulator, however, research is ongoing to dig deeper into how Livagen can usher researchers into discerning new layers of organisms’ aging processes and senescence. Experimental studies in the Livagen peptide report that it shows minimal side effects, and ranges from low oral to excellent subcutaneous bioavailability. Livagen is limited to educational and scientific purposes only, and is not for human consumption.